Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Oct;26(10):4366-4374.
doi: 10.1111/dom.15784. Epub 2024 Jul 22.

Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching

Hideyuki Iwamoto  1 , Tomohiko Kimura  1 , Yoshiro Fushimi  1 , Masahiro Iwamoto  2 , Fuminori Tatsumi  1 , Junpei Sanada  1 , Yuichiro Iwamoto  1 , Yukino Katakura  1 , Masashi Shimoda  1 , Shuhei Nakanishi  1 , Tomoatsu Mune  1 , Kohei Kaku  1 , Hideaki Kaneto  1
Affiliations
Observational Study

Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching

Hideyuki Iwamoto et al. Diabetes Obes Metab. 2024 Oct.

Abstract

Aim: Recently, the development of the oral glucagon-like peptide-1 receptor agonist semaglutide has drawn a great deal of attention. This study aimed to compare the effectiveness of oral glucagon-like peptide-1 receptor agonist semaglutide and dipeptidyl peptidase-4 (DPP-4) inhibitors on glycaemic control and several metabolic parameters in patients with type 2 diabetes mellitus over a 6-month period.

Methods: Fifty-nine participants were included, and we compared various clinical parameters between before and after switching from DPP-4 inhibitors to oral semaglutide in 'study 1' (pre-post comparison) and set the control group using the propensity score matching method in 'study 2'.

Results: In 'study 1', 6 months after the switching, the glycated haemoglobin value was significantly reduced from 7.5% to 7.0%, and the body mass index was also decreased from 29.7 kg/m2 to 28.8 kg/m2. Such effects were more clearly observed in participants whose glycaemic control was poor. In 'study 2', after 1:1 propensity score matching, 51 participants from each group were matched, and glycaemic control as well as body weight management were improved in the switching group compared with the DPP-4 inhibitor continuation group over the 6-month observation period.

Conclusion: In this study, including obese participants with poor glycaemic control, switching DPP-4 inhibitors to oral semaglutide showed more beneficial effects on both glycaemic and weight control, irrespective of age, body weight and diabetes duration. Therefore, we should bear in mind that it would be better to start using an oral semaglutide in clinical practice, particularly in obese participants with poor glycaemic control with DPP-4 inhibitors.

Keywords: body mass index; dipeptidyl peptidase‐4 inhibitors; glucagon‐like peptide‐1 receptor agonist; glycated haemoglobin; oral semaglutide.

PubMed Disclaimer

References

REFERENCES

    1. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. prospective diabetes study group. Diabetes. 1995;44:1249‐1258.
    1. Butler AE, Janson J, Bonner‐Weir S, Ritzel R, Rizza RA, Butler PC. Beta‐cell deficit and increased beta‐cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102‐110.
    1. Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study). Diabetes Care. 2019;42:416‐426.
    1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405‐412.
    1. Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract. 2005;59:1345‐1355.

Publication types

MeSH terms

LinkOut - more resources